Regeneron Ties Future U.S. Drug Prices to Global Benchmarks

Regeneron Pharmaceuticals has formalized an agreement with the U.S. government that structurally links Medicaid pricing and future U.S. launch prices to benchmarks set in other developed countries, a model that, if adopted more broadly, would reshape how manufacturers approach global pricing strategy and domestic market access planning.

Under the terms of the agreement, Regeneron will lower Medicaid prices based on prices in other developed countries and will align U.S. prices of future medicines with prices set in that defined group of countries. Praluent (alirocumab), the company's PCSK9 inhibitor, will be made available for direct patient purchase at the most-favored-nation price through the TrumpRx.gov platform. Separately, Regeneron's recently FDA-approved gene therapy Otarmeni (lunsotogene parvec-cwha) -- indicated for severe to profound hearing loss due to otoferlin gene variants -- will be offered at no cost to patients in the U.S.

Regulatory and manufacturing context: Regeneron will not be subject to future pricing mandates and will receive tariff relief for three years through an agreement with the U.S. Department of Commerce, under which the company has committed to certain domestic activities and investments. The company has indicated it will continue its existing investment in domestic R&D and manufacturing capacity, a commitment that carries operational implications for site planning, technology transfer timelines, and supply chain localization across its U.S. network.

The agreement was announced at the White House, where Regeneron co-founders Leonard Schleifer, M.D., Ph.D., and George Yancopoulos, M.D., Ph.D., joined President Donald J. Trump and members of his Administration. Schleifer stated the agreement responds to four requests set forth in a July 31st presidential letter. The source for this article is a Regeneron press release distributed via GlobeNewswire on April 23, 2026.